CARHSP1 and prostate carcinoma: On the other hand, both progression-free survival (PFS) and disease-free interval (DFI) of prostate cancer patients in the CARHSP1 high-expression group were significantly shorter than in the CARHSP1 low-expression group from the GSCA PCa database (Fig. 1G and H).